Skip to main content

Advertisement

Table 5 Diagnostic profiles of VEGF levels available before second and third cycles of chemotherapy for the prediction of cancer progression or response to therapy

From: Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer

  AUC Cut-off Sensitivity % Specificity % LR
  (95% CI) VEGF (pg/mL) (95% CI) (95% CI)  
Evaluation 1 (R + NC vs P)      
VEGF BV2 0.805 (0.675-0.935) 312.6 71.4 (42.0-90.4) 71.4 (51.1-86.0) 2.5
VEGF BV3 0.895 (0.797-0.993) 355.4 85.7 (56.2-97.5) 89.3 (70.6-97.2) 8.0
Evaluation 2 (R vs NC + P)      
VEGF BV2 0.724 (0.553-0.893) 232.1 76.9 (55.9-90.2) 75.0 (47.4-91.7) 3.1
VEGF BV3 0.817 (0.679-0.956) 261.0 76.9 (55.9-90.2) 75.0 (47.4-91.7) 3.1
  1. BV2, and BV3, baseline VEGF levels before therapy cycle 2 to 3, respectively; AUC, area under receiver operating characteristic
  2. (ROC) curve; 95% CI, 95% confidence interval; LR, likelihood ratio; R, remission; NC, no change; P, progression.